Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in primary Sjögren's Syndrome (Rho plus)
NCT06203457Phase 2Completed
- Sponsor
- argenx
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Antibody Fragments
- Countries
- 3
01
Overview
A Phase 2 trial of efgartigimod alfa in primary Sjögren's syndrome, sponsored by argenx. Started Nov 2023; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT06203457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06203457.